1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2017
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article
- 2016
-
Mark
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
(
- Contribution to journal › Article
-
Mark
Enzalutamide in metastatic prostate cancer before chemotherapy
(
- Contribution to journal › Article